Which medication is contraindicated for use in a patient with heart failure and type 2 diabetes due to potential worsening of heart failure?

Which medication is contraindicated for use in a patient with heart failure and type 2 diabetes due to potential worsening of heart failure?

• A. Alogliptin
• B. Saxagliptin
• C. Semaglutide
• D. Empagliflozin

Answer: (B)

Saxagliptin is considered contraindicated in patients with heart failure and type 2 diabetes because clinical studies have demonstrated an increased risk of hospitalization for heart failure associated with its use. The SAVOR-TIMI 53 trial specifically highlighted that saxagliptin use was linked to a higher incidence of heart failure-related events compared to placebo. This is particularly concerning for patients who already have heart failure, as the medication's effects could exacerbate their condition and lead to worsening clinical outcomes. In contrast, the other medications listed have either not shown similar risks or have been studied and found to be neutral or beneficial concerning heart failure. For instance, alogliptin does not have the same association with heart failure risk, and both semaglutide and empagliflozin have shown cardiovascular benefits and even improvement in heart failure outcomes in some patient subgroups. Thus, saxagliptin stands out as the only medication strongly recommended to be avoided in this specific patient population due to its implications for heart failure worsening.

Saxagliptin is considered contraindicated in patients with heart failure and type 2 diabetes because clinical studies have demonstrated an increased risk of hospitalization for heart failure associated with its use. The SAVOR-TIMI 53 trial specifically highlighted that saxagliptin use was linked to a higher incidence of heart failure-related events compared to placebo. This is particularly concerning for patients who already have heart failure, as the medication's effects could exacerbate their condition and lead to worsening clinical outcomes.

In contrast, the other medications listed have either not shown similar risks or have been studied and found to be neutral or beneficial concerning heart failure. For instance, alogliptin does not have the same association with heart failure risk, and both semaglutide and empagliflozin have shown cardiovascular benefits and even improvement in heart failure outcomes in some patient subgroups. Thus, saxagliptin stands out as the only medication strongly recommended to be avoided in this specific patient population due to its implications for heart failure worsening.